---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-22-000004"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2022-02-04T23:59:59+00:00"
generated_at: "2026-06-27T11:19:48.325022+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q4 revenue surges 104% to $4.95B; REGEN-COV writedown $232M

## Summary
- Q4 GAAP diluted EPS $19.69 vs $10.24; non-GAAP EPS $23.72 vs $9.53.
- EYLEA U.S. net sales $1.55B (+15% YoY); full year $5.79B (+17%).
- $232M writedown of REGEN-COV inventory due to Omicron; EUA revised to exclude Omicron regions.
- FY2022 non-GAAP guidance: R&D $2.8B-$3.0B; SG&A $1.65B-$1.77B; gross margin 90-92%.
- Board authorized $3B share repurchase program.

## SEC filing metadata
- accession: 0001804220-22-000004
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2022-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422022000004/0001804220-22-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422022000004/regn-20220204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-22-000004
- JSON: https://secwatch.observer/filing/0001804220-22-000004.json
- Plain text: https://secwatch.observer/filing/0001804220-22-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.